IC
JANX icon

Ikarian Capital’s Janux Therapeutics JANX Stock Holding History

Ikarian Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-54,691
Closed -$1.34M – 200
2025
Q3 		$1.34M Sell
54,691
-75,000
-58% -$1.83M 0.14% 113
2025
Q2 		$3M Hold
129,691
– – 0.58% 53
2025
Q1 		$3.5M Buy
129,691
+55,000
+74% +$2.07M 0.43% 53
2024
Q4 		$4M Buy
+74,691
New +$3.95M 0.54% 55

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ikarian Capital's JANX Position: Q4 2025 in Review

Ikarian Capital sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 54,691 shares — an estimated $1.34M sold.

Ikarian Capital first reported a position in JANX in Q4 2024 and held it in 4 quarters. The position peaked at $4M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Ikarian Capital reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 54,691 Janux Therapeutics shares in Q4 2025, an estimated $1.34M.
  • Ikarian Capital first reported a position in Janux Therapeutics in Q4 2024 and held it in 4 quarters.
  • Ikarian Capital's Janux Therapeutics position peaked at $4M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.